Clinical Trial Detail

NCT ID NCT03698019
Title Pembrolizumab in Treating Patients With Stage III-IV High-Risk Melanoma Before and After Surgery
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

melanoma

Therapies

Pembrolizumab

Age Groups: senior adult

No variant requirements are available.